Scarica l'app Stockscreener
230.84
0.68%
-1.57
Dopo l'orario di chiusura:
230.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$232.41
Aprire:
$234.89
Volume 24 ore:
1.34M
Relative Volume:
1.26
Capitalizzazione di mercato:
$33.63B
Reddito:
$5.40B
Utile/perdita netta:
$1.49B
Rapporto P/E:
22.82
EPS:
10.1168
Flusso di cassa netto:
$1.78B
1 W Prestazione:
-8.71%
1M Prestazione:
-8.60%
6M Prestazione:
-14.55%
1 anno Prestazione:
+5.06%
Intervallo 1D:
$230.21
$235.80
Intervallo di 1 settimana:
$230.21
$253.13
Portata 52W:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
230.84 | 33.63B | 5.40B | 1.49B | 1.78B | 10.12 |
|
ISRG
Intuitive Surgical Inc
|
472.16 | 167.68B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
159.36 | 45.33B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
77.32 | 37.69B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
41.46 | 33.65B | 28.43B | 1.16B | 1.26B | 1.4457 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
3 Reasons Not to Sleep on ResMed Stock - AOL.com
2Xideas AG Acquires 8,397 Shares of ResMed Inc. $RMD - MarketBeat
Landscape Capital Management L.L.C. Boosts Stake in ResMed Inc. $RMD - MarketBeat
Russell Investments Group Boosts Stake in ResMed - National Today
Mackenzie Financial Corp Trims Stock Position in ResMed Inc. $RMD - MarketBeat
Russell Investments Group Ltd. Has $30.85 Million Position in ResMed Inc. $RMD - MarketBeat
Bank of Montreal Can Sells 128,166 Shares of ResMed Inc. - National Today
Bank of Montreal Can Sells 128,166 Shares of ResMed Inc. $RMD - MarketBeat
ChartWatch ASX Scans: Whitehaven Coal, New Hope Corp, Yancoal, CSL, Charter Hall, Resmed, Seek, Zip Co. - Market Index
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Legal & General Group Plc Reduces ResMed Inc. Stake - National Today
Legal & General Group Plc Reduces Stake in ResMed Inc. - National Today
Schroder Investment Management Group Boosts Stake in ResMed Inc. - National Today
Is ResMed Stock Underperforming the Nasdaq? - Barchart
Schroder Investment Management Group Boosts Stock Holdings in ResMed Inc. $RMD - MarketBeat
Legal & General Group Plc Has $262.29 Million Position in ResMed Inc. $RMD - MarketBeat
Is It Time To Reconsider ResMed (RMD) After Recent Share Price Pullback - simplywall.st
ChartWatch ASX Scans: Lynas Rare Earths, Finder Energy, Lindian Resources, Resmed, Treasury Wine Estates, Harvey Norman - Market Index
ResMed (RMD) Stock Trades Down, Here Is Why - Yahoo Finance
Hedge Fund and Insider Trading News: Bill Ackman, Stanley Druckenmiller, Ken Griffin, Caxton Associates, Braidwell LP, Rokos Capital Management, ResMed Inc (RMD), Accel Entertainment Inc (ACEL), and More - Insider Monkey
ResMed (NYSE:RMD) CEO Sells $1,252,890.73 in Stock - MarketBeat
Resmed Insider Sold Shares Worth $1,252,902, According to a Recent SEC Filing - marketscreener.com
ResMed (NYSE: RMD) CEO sells 4,991 shares after option exercise - Stock Titan
ResMed Inc. $RMD Shares Sold by Swiss National Bank - MarketBeat
Baird Adjusts Price Target on ResMed to $272 From $281, Maintains Neutral Rating - marketscreener.com
Korea Investment CORP Has $19.52 Million Stake in ResMed Inc. $RMD - MarketBeat
City of Greenwood welcomes Resmed to town - Local News Digital
3 Reasons Not to Sleep on ResMed Stock - The Motley Fool
Jefferies Financial Group Inc. Grows Position in ResMed Inc. $RMD - MarketBeat
American Century Companies Inc. Sells 94,015 Shares of ResMed Inc. $RMD - MarketBeat
Assessing ResMed (RMD) Valuation As New Greenwood Distribution Hub Targets North American Growth - Sahm
ResMed Inc. (NYSE:RMD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ResMed (HAM:RME) Graham Number : €58.05 (As of Dec. 2025) - GuruFocus
Director sale notice: RMD (NYSE: RMD) files Form 144 to sell 4,991 shares - Stock Titan
ResMed Inc (HAM:RME) DCF Valuation - GuruFocus
ResMed (HAM:RME) 10-Year ROIIC % : 21.91% (As of Jun. 2025) - GuruFocus
ResMed (HAM:RME) Issuance of Stock : €67 Mil (TTM As of Dec. 2025) - GuruFocus
Healthcare Sector Analysis: Natera, ResMed, Globus Medical Driving InnovationNews and Statistics - IndexBox
Dundas Partners LLP Acquires 22,933 Shares of ResMed Inc. $RMD - MarketBeat
First Trust Advisors LP Buys 329,588 Shares of ResMed Inc. $RMD - MarketBeat
Neuberger Berman Group LLC Boosts Position in ResMed Inc. $RMD - MarketBeat
Blair William & Co. IL Trims ResMed Inc. Stake - National Today
Dimensional Fund Advisors LP Has $231.59 Million Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by Blair William & Co. IL - MarketBeat
ResMed Inc. stock rises Monday, outperforms market - MSN
Crossmark Global Holdings Inc. Purchases 17,487 Shares of ResMed Inc. $RMD - MarketBeat
Marietta Investment Partners LLC Invests $2.70 Million in ResMed Inc. $RMD - MarketBeat
Resmed director Farrell sells $520k in stock - Investing.com
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
ResMed Director Peter Farrell Plans Modest Insider Share Sale Under Rule 144 - TipRanks
ResMed (NYSE:RMD) Director Peter Farrell Sells 2,000 Shares - MarketBeat
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
1.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):